Been digging into Supernus Pharmaceuticals ($SUPN) and some interesting stuff is happening. So Jack Khattar, the CEO, just lined up appearances at two major investor conferences in March - Barclays Healthcare and Jefferies Biotech on the Beach. Standard CEO move to boost visibility with investors, right? But here's where it gets spicy.

Looking at the insider trading activity over the last 6 months, Jack Khattar himself dumped 250,000 shares for around $9.1 million. Zero purchases, just sales. And he's not alone - basically all the insiders are selling. The Sr. VP of IP sold over $1.2 million worth, the Chief Medical Officer, the COO, everyone's moving shares. That's 15 sales transactions in 6 months with zero buys. You know what that usually signals.

On the flip side, institutional investors are all over the place. Some hedge funds like Armistice Capital and Polar Capital are cutting positions pretty hard - we're talking millions in Q4 2024. But then you've got Woodline Partners adding 235k shares and BNP Paribas jumping in with over 200k shares. The mixed institutional activity is interesting, especially when insiders are consistently exiting.

Supernus is doing CNS stuff - ADHD treatments, Parkinson's therapies, epilepsy drugs. Not a bad portfolio. But when your CEO is out there doing the conference circuit while simultaneously cashing out, it makes you wonder what the real story is behind closed doors. Jack Khattar's visibility at these events might be less about confidence and more about managing expectations.